Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential

作     者：Chenglong Wang Wencai Guan Rong Chen Yael Levi-Kalisman Yichun Xu Liwen Zhang Min Zhou Guoxiong Xu Hongjing Dou Chenglong Wang;Wencai Guan;Rong Chen;Yael Levi-Kalisman;Yichun Xu;Liwen Zhang;Min Zhou;Guoxiong Xu;Hongjing Dou

作者机构：The State Key Laboratory of Metal Matrix CompositesSchool of Materials Science and EngineeringShanghai Jiao Tong UniversityShanghai200240China Research Center for Clinical ResearchJinshan HospitalFudan UniversityShanghai200540China Department of Respiratory and Critical Care MedicineRuijin HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai200025China Institute of Respiratory DiseasesSchool of MedicineShanghai Jiao Tong UniversityShanghai200025China The Center for Nanoscience and Nanotechnology and the Institute of Life SciencesHebrew University of JerusalemJerusalem91905Israel Shanghai Biochip Co.Ltd.National Engineering Center for Biochip at ShanghaiShanghai201203China 

出 版 物：《Nano Research》 (纳米研究（英文版）)

年 卷 期：2020年第13卷第11期

页      面：3110-3122页

核心收录：

学科分类：07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 0702[理学-物理学] 

基　　金：supported by the National Natural Science Foundation of China(Nos.21871180 and 81872121) the“Shuguang Program”supported by the Shanghai Education Development Foundation and the Shanghai Municipal Education Commission(No.17SG12) the Program for Professor of Special Appointment(Eastern Scholar)at Shanghai Institutions of Higher Learning(No.SHDP201802) the Science and Technology Commission of Shanghai Municipality(No.18520710300 and 17ZR1404100) the Biomedical Interdisciplinary Research Foundation of SJTU(No.YG2019QNB34) 

主　　题：glycan nanoparticle FACS assays drug resistance tumor heterogeneity diagnose 

摘      要：Herein we develop a unique differentiated-uptake strategy capable of efficient and high-purity isolation of genuine drug-resistant(DR)cells from three types of drug-surviving cancer cells,which include paclitaxel-surviving human ovarian OVCAR-3 cancer cells and human lung carcinoma A549/Taxol cells,and doxorubicin-surviving human immortalized myelogenous leukemia K562/ADR *** using this strategy which relies on fluorescent glycan nanoparticle(FGNP)-based fluorescence-activated cell sorting(FACS)assays,two subpopulations with distinct fluorescences existing in drug-surviving OVCAR-3 cells were separated,and we found that the lower fluorescence(LF)subpopulation consisted of DR cells,while the higher fluorescence(HF)subpopulation was comprised of non-DR ***,the DR cells and their progenies were found distinct in their increased expression of drug-resistant *** intriguingly,by using the FGNP-based FACS assay to detect DR/non-DR phenotypes,we found that the DR phenotype had a potential to differentiate into the non-DR progeny,which demonstrates the differentiation feature of stem-like cancer *** research disclosed that the assay can quantitatively detect the degree of drug resistance in DR cells,as well as the reversal of drug resistance that are tackled by various therapeutic *** strategy thus paves the way to develop theranostic approaches associated with chemotherapy-resistance and cancer stemness.